Abstract
Generic formulations represent a way to reduce the costs of brand compounds when their patent is expired. While, the bio-equivalence in generic drugs is guaranteed, some excipients as well as dyes could be different and this could reduce the drug safety. Herein, we report the development of Adverse Drug Reactions (ADRs) in two patients after the switch from brand to generic formulations. We have tested cytochrome P450 enzymes expression as well as drug serum levels. None of these markers were altered. Checking deeply into both patient’s medical history, they harbored poly-sensitivity or allergy to pollen and graminacea and used different active ingredients for different health problems coming from the same generic company Almus®. This company used different dyes and excipients compared to the branded drugs made by distinguished companies. In conclusion, we strongly suggest to both pharmacists and physicians to be careful in giving the advice to change the drug, thinking to reduce health sanitary costs without considering the personal clinical history of each one. Paradoxically this behavior is causing other health issues, bringing to an increase of the overall costs for patients as well as for National Health System.
Keywords: Adverse drug reactions, brand drug, generic drug.
Current Drug Safety
Title:Recognizing Severe Adverse Drug Reactions: Two Case Reports After Switching Therapies to the Same Generic Company
Volume: 11 Issue: 1
Author(s): Luca Gallelli, Giuseppe Gallelli, Giuseppe Codamo, Angela Argentieri, Andzelika Michniewicz, Antonio Siniscalchi, Roberta Stefanelli, Erika Cione, Maria C. Caroleo, Paola Longo and Giovambattista De Sarro
Affiliation:
Keywords: Adverse drug reactions, brand drug, generic drug.
Abstract: Generic formulations represent a way to reduce the costs of brand compounds when their patent is expired. While, the bio-equivalence in generic drugs is guaranteed, some excipients as well as dyes could be different and this could reduce the drug safety. Herein, we report the development of Adverse Drug Reactions (ADRs) in two patients after the switch from brand to generic formulations. We have tested cytochrome P450 enzymes expression as well as drug serum levels. None of these markers were altered. Checking deeply into both patient’s medical history, they harbored poly-sensitivity or allergy to pollen and graminacea and used different active ingredients for different health problems coming from the same generic company Almus®. This company used different dyes and excipients compared to the branded drugs made by distinguished companies. In conclusion, we strongly suggest to both pharmacists and physicians to be careful in giving the advice to change the drug, thinking to reduce health sanitary costs without considering the personal clinical history of each one. Paradoxically this behavior is causing other health issues, bringing to an increase of the overall costs for patients as well as for National Health System.
Export Options
About this article
Cite this article as:
Gallelli Luca, Gallelli Giuseppe, Codamo Giuseppe, Argentieri Angela, Michniewicz Andzelika, Siniscalchi Antonio, Stefanelli Roberta, Cione Erika, Caroleo C. Maria, Longo Paola and Sarro De Giovambattista, Recognizing Severe Adverse Drug Reactions: Two Case Reports After Switching Therapies to the Same Generic Company, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886311207040309
DOI https://dx.doi.org/10.2174/1574886311207040309 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Assessment of Acute Coronary Syndromes: Focus on Novel Biomarkers
Current Medicinal Chemistry Implantable Medical Devices and Tissue Engineering: An Overview of Manufacturing Processes and the Use of Polymeric Matrices for Manufacturing and Coating their Surfaces
Current Medicinal Chemistry Gender Disparities on Access to Care and Coronary Disease Management
Current Pharmaceutical Design Modulators of Vascular Sex Hormone Receptors and their Effects in Estrogen-Deficiency States Associated with Menopause
Recent Patents on Cardiovascular Drug Discovery Genistein: A Boon for Mitigating Ischemic Stroke
Current Topics in Medicinal Chemistry Contraindications for Anticoagulation in Older Patients with Atrial Fibrillation: A Narrative Review
Current Drug Safety Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors
Current Medicinal Chemistry Iron Involvement in Multiple Signaling Pathways of Atherosclerosis: A Revisited Hypothesis
Current Medicinal Chemistry Chios Gum Mastic: A Review of its Biological Activities
Current Medicinal Chemistry Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment
Current Topics in Medicinal Chemistry Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design Cytochrome P450 2C8 and Drug Metabolism
Current Topics in Medicinal Chemistry A Yeast Extract High in Bioactive Peptides has a Blood-Pressure Lowering Effect in Hypertensive Model
Current Medicinal Chemistry Neutrophil to Lymphocyte (N/L) and Platelet to Lymphocyte (P/L) Ratios in Differentiating Acute Heart Failure from Respiratory Infection
Current Vascular Pharmacology Recent Advances in Fe-MOF Compositions for Biomedical Applications
Current Medicinal Chemistry The Cardiovascular and Cardiac Actions of Ecstasy and its Metabolites
Current Pharmaceutical Biotechnology Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Xanthine Derivatives in the Heart: Blessed or Cursed?
Current Medicinal Chemistry Biomarkers as a Guide of Medical Treatment in Cardiovascular Diseases
Current Medicinal Chemistry